Stock-based compensation expense was included in general and administrative and research and development costs as follows in the accompanying condensed statements of comprehensive loss for the three and six-month periods indicated below (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Research and development	$	439	$	282	$	798	$	566
General and administrative	968		614		2,073		1,243
Total stock-based compensation	$	1,407	$	896	$	2,871	$	1,809

During the three and six months ended June 30, 2026, 1,115,000 stock options were granted to directors, officers, and employees. During the three and six months ended June 30, 2025, 797,144 and 2,059,829 stock options were granted, respectively, to directors, officers and employees.

During the three and six months ended June 30, 2026, the Company granted an aggregate of 170,569 and 3,172,708 RSUs, respectively, to directors, officers, and employees. The weighted average grant date fair value of the RSUs granted during the three and six months ended June 30, 2026 was $5.54 and $2.65, respectively.

During the three and six months ended June 30, 2025, the Company granted an aggregate of 706,528 and 1,455,361 RSUs, respectively, to directors, officers, and employees. The weighted average grant date fair value of the RSUs granted during the three and six months ended June 30, 2025 was $0.95 during each of these periods.

The Company granted stock for services in the amount of 118,465 and 84,243 common shares during the three and six month periods ended June 30, 2026 and 2025, respectively. The awards were granted to members of the Board who elected to receive their Board compensation in the form of stock for services. The weighted average fair value of the shares granted was $2.01 per share and $1.26 during the three and six months ended June 30, 2026 and 2025, respectively, and were 100% vested upon issuance.